Proton pump inhibitor usage and the risk of myocardial infarction in the general population

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Shah, Nigam H ^a   LePendu, Paea ^a   Bauer Mehren, Anna ^a   Ghebremariam, Yohannes T ^b   Iyer, Srinivasan V ^a   Marcus, Jake ^c   Nead, Kevin T ^d   Cooke, John P ^b   Leeper, Nicholas J ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Practice Fusion Inc   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICLOPIDINE;

ADULT; ADVERSE OUTCOME; ALGORITHM; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; MIDDLE AGED; YOUNG ADULT;

ADULT; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS; TICLOPIDINE; YOUNG ADULT;

EID: 84936774522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124653     Document Type: Article

References (48)

1. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med, 2011. 78(1): p. 39-49. doi: 10.3949/ccjm.77a.10087 PMID: 21199906
2. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med, 2010. 170(9): p. 747-8. doi: 10.1001/archinternmed.2010.64 PMID: 20458079
3. U.S. Food and Drug Administration (FDA). FDA Drug Safety Podcast for Healthcare Professionals: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.htm, 2009.
4. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996. 348(9038): p. 1329-39. PMID: 8918275
5. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA: the journal of the American Medical Association, 2009. 301(9): p. 937-44. doi: 10.1001/jama.2009.261 PMID: 19258584
6. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and NonST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation, 2011. 123(5): p. 474-82. doi: 10.1161/CIRCULATIONAHA.110.965640 PMID: 21262992
7. Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH Sørensen R Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Annals of internal medicine, 2010. 153(6): p. 378-86. doi: 10.7326/0003-4819-153-6-201009210-00005 PMID: 20855802
8. Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ, 2012. 345: p. e4388. doi: 10.1136/bmj.e4388 PMID: 22782731
9. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2009. 374(9694): p. 989-97. doi: 10.1016/S0140-6736(09)61525-7 PMID: 19726078
10. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010. 363(20): p. 1909-17. doi: 10.1056/NEJMoa1007964 PMID: 20925534
11. Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 2010. 56(4): p. 321-41. doi: 10.1016/j.jacc.2010.05.013 PMID: 20633831
12. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 2011. 342: p. d2690. doi: 10.1136/bmj.d2690 PMID: 21562004
13. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation, 2012. 125(8): p. 978-86. doi: 10.1161/CIRCULATIONAHA.111.032912 PMID: 22261200
14. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, Anastasakou E, Kotsi P, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol, 2009. 54(2): p. 163-8. doi: 10.1097/FJC.0b013e3181af6d9c PMID: 19568178
15. Dunn SP, Steinhub, SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc, 2013. 2(1): p. e004564. doi: 10.1161/JAHA.112.004564 PMID: 23525436
16. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation, 2013. 128(8): p. 845-53. doi: 10.1161/CIRCULATIONAHA.113.003602 PMID: 23825361
17. Cooke JP, Ghebremariam YT. DDAH says NO to ADMA. Arterioscler Thromb Vasc Biol, 2011. 31(7): p. 1462-4. doi: 10.1161/ATVBAHA.111.228833 PMID: 21677286
18. Cooke JP. DDAH: a target for vascular therapy? Vasc Med, 2010. 15(3): p. 235-8. doi: 10.1177/1358863X10362605 PMID: 20385710
19. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arteriosclerosis, thrombosis, and vascular biology, 2006. 26(11): p. 2536-40. PMID: 16931791
20. Wilson A, Shin D, Weatherby C, Harada R, Ng M, Nair N, et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vascular medicine, 2010. 15(4): p. 267-74. doi: 10.1177/1358863X10364552 PMID: 20484311
21. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. International journal of cardiology, 2011. 153(2): p. 135-40. doi: 10.1016/j.ijcard.2011.06.120 PMID: 21794936
22. Ari H, Ari S, Erdoʇan E, Tiryakioʇlu O, U¨stündaʇ Y, Huysal K, et al. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart and vessels, 2010. 25(1): p. 19-26. doi: 10.1007/s00380-009-1158-x PMID: 20091394
23. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation, 2004. 109(15): p. 1813-8. PMID: 15096461
24. Böger RH, Maas R, Schulze F, Schwedhelm E. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation, 2009. 119(12): p. 1592-600. doi: 10.1161/CIRCULATIONAHA.108.838268 PMID: 19289633
25. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol, 2014. 177(1): p. 292-7. doi: 10.1016/j.ijcard.2014.09.036 PMID: 25499395
26. LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther, 2013. 93(6): p. 547-55. doi: 10.1038/clpt.2013.47 PMID: 23571773
27. LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Learning Signals of Adverse Drug-Drug Interactions from the Unstructured Text of Electronic Health Records in AMIA Summit on Translational Bioinformatics. 2013: San Francisco, CA. p. 83-87.
28. Nead KT, Zhou MJ, Caceres RD, Sharp SJ, Wehner MR, Olin J, et al. Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography. The American journal of cardiology, 2013. 111(6): p. 851-6. doi: 10.1016/j.amjcard.2012.11.055 PMID: 23290308
29. Nead KT, Cooke JP, Olin JW, Leeper NJ. Alternative ankle-brachial index method identifies additional at-risk individuals. J Am Coll Cardiol, 2013. 6: p. 553-9. doi: 10.1016/j.jacc.2013.04.061 PMID: 23707317
30. Lowe HJ, Ferris TA, Hernandez PM, Weber SC. STRIDE-An integrated standards-based translational research informatics platform. AMIA Symposium, 2009. 2009: p. 391-5.
31. Honig PK. Advancing the science of pharmacovigilance. Clin Pharmacol Ther, 2013. 93(6): p. 474-5. doi: 10.1038/clpt.2013.60 PMID: 23689213
32. Breiman L. Statistical Modeling: The Two Cultures. Statistical Science, 2001. 16(9): p. 199-231.
33. Halevy A, Norvig P, Pereira F. The unreasonable effectiveness of data. Intelligent Systems, IEEE, 2009. 24(2): p. 8-12.
34. Einav L, Levin J. Economics in the age of big data. Science, 2014. 346(6210): p. 12430891-12430896.
35. Coloma PM, Avillach P, Salvo F, Schuemie M. J, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug safety: an international journal of medical toxicology and drug experience, 2013. 36(1): p. 13-23.
36. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. Journal of the American College of Cardiology, 2008. 51(3): p. 256-60. doi: 10.1016/j.jacc.2007.06.064 PMID: 18206732
37. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol, 2006. 59(5): p. 437-47. PMID: 16632131
38. Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Buttò V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA internal medicine, 2013. 173(7): p. 518-23. doi: 10.1001/jamainternmed.2013.2851 PMID: 23460307
39. Maggio M, Corsonello A. Harmful effects of proton pump inhibitors: discrepancies between observational studies and randomized clinical trials-reply. JAMA Intern Med, 2013. 173(16): p. 1559-60. doi: 10.1001/jamainternmed.2013.8459 PMID: 24030767
40. U.S. Food and Drug Administration. FDA Announces New Warning on Plavix: Avoid Use with Prilosec/Prilosec OTC. 2009 11/5/2014]; Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm.
41. Sossalla S, Schotola H, Schmitto J, Toischer K, Sohns C, Schwörer H, et al. Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium. J Cardiovasc Surg (Torino), 2011. 52(3): p. 437-44. PMID: 21577199
42. Schillinger W, Teucher N, Sossalla S, Kettlewell S, Werner C, Raddatz D, et al. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation, 2007. 116(1): p. 57-66. PMID: 17576869
43. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep, 2010. 12(6): p. 448-57. doi: 10.1007/s11894-010-0141-0 PMID: 20882439
44. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med, 2005. 10 Suppl 1: p. S27-33. PMID: 16444866
45. Oudit GY, Bakal JA, McAlister FA, Ezekowitz JA. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. Eur J Heart Fail, 2011. 13(11): p. 1211-5. doi: 10.1093/eurjhf/hfr104 PMID: 21831912
46. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl, 2003. 4(4): p. 33-40. PMID: 14664901
47. Leeper NJ, Bauer-Mehren A, Iyer SV, LePendu P, Olson C, Shah NH. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes. PLoS ONE, 2013. 8(5): p. e63499. doi: 10.1371/journal.pone.0063499 PMID: 23717437
48. Friedman CP, Wong AK, Blumenthal D. Achieving a nationwide learning health system. Sci Transl Med, 2010. 2(57): p. 57cm29. doi: 10.1126/scitranslmed.3001456 PMID: 21068440